Here are the DEF 14A proxy statements from Salarius Pharmaceuticals, Inc. (SLRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SLRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLRX filings page.
Decoy Therapeutics Inc. is asking stockholders to vote at its 2026 virtual annual meeting on July 14, 2026. Holders of 531,968 common shares as of May 22, 2026 can participate and vote online.
Stockholders will elect three Class II directors, including current CEO Frederick E. Pierce and director Jonathan Lieber, and first-time nominee Patricia Gauthier, each to serve until the 2029 meeting. They will also cast a non-binding advisory vote on executive compensation and vote on ratifying Ernst & Young LLP as independent auditor for 2026. The board recommends voting “FOR” all three proposals.
The proxy outlines board structure, committee memberships, independence determinations and director pay, including reduced cash retainers. It details 2025 compensation for top executives, such as base salaries, a $225,000 transaction bonus paid to CFO Mark Rosenblum tied to a merger closing, and severance and consulting arrangements for former CEO David Arthur, along with new employment agreements and severance terms for senior leaders hired through the merger.